MiR-181a-2-3p as a potential diagnostic and prognostic marker for myelodysplastic syndrome

ABSTRACT Objective: Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder with a high propensity to develop into acute myeloid leukemia (AML). Although abnormal microRNA expression has been implicated in MDS, the exact role of miR-181a-2-3p has not been entirely elucidated. Here, we investigated miR-181a-2-3p levels in bone marrow (BM), and described its utility as a potential indicator for MDS diagnosis and prognosis. Methods: We evaluated miR-181a-2-3p expression in BM samples of 54 newly diagnosed MDS cases, 16 sAML patients and 32 healthy donors and then assessed its association with clinical characteristics and its potential value for MDS diagnosis and prognosis. Results: Compared with healthy controls, miR-181a-2-3p levels were decreased in the total cohort of MDS patients. Additionally, in MDS patients with secondary AML (sAML), miR-181a-2-3p was over-expressed relative to levels in those without this form. The areas under the curve of receiver operating characteristic curves were 0.700 and 0.750 to distinguish MDS patients from controls and sAML from newly diagnosed MDS, respectively. Kaplan–Meier analysis showed a positive correlation between miR-181a-2-3p expression and overall survival (OS). Further, multivariate analysis indicated that miR-181a-2-3p was an independent prognostic index for MDS with respect to OS. Conclusion: Decreased miR-181a-2-3p expression in MDS patients may be considered as one of the underlying markers reflecting MDS progression and prognosis.

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  Wenqi Wu,et al.  Microarray analysis of differentially expressed microRNAs in myelodysplastic syndromes , 2020, Medicine.

[3]  B. Baradaran,et al.  microRNA-181 serves as a dual-role regulator in the development of human cancers. , 2019, Free radical biology & medicine.

[4]  I. Berindan‐Neagoe,et al.  Altered expression of miR-181 affects cell fate and targets drug resistance-related mechanisms. , 2019, Molecular aspects of medicine.

[5]  H. Pati,et al.  Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes: Molecular Pathogenetic Mechanisms and Their Implications , 2019, Indian Journal of Hematology and Blood Transfusion.

[6]  Xiao-mei Zhang,et al.  Prognostic value of a two‐microRNA signature for papillary thyroid cancer and a bioinformatic analysis of their possible functions , 2018, Journal of cellular biochemistry.

[7]  Zaili Zhang,et al.  SPAG6 silencing induces apoptosis in the myelodysplastic syndrome cell line SKM‑1 via the PTEN/PI3K/AKT signaling pathway in vitro and in vivo. , 2018, International journal of oncology.

[8]  R. Chhabra,et al.  let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer , 2018, Scientific Reports.

[9]  Ryan M. O’Connell,et al.  MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts. , 2017, Blood.

[10]  Zhongyan Zhao,et al.  Upregulation of miR-181a suppresses the formation of glioblastoma stem cells by targeting the Notch2 oncogene and correlates with good prognosis in patients with glioblastoma multiforme. , 2017, Biochemical and biophysical research communications.

[11]  Annette S. Kim,et al.  MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia , 2017, Leukemia & lymphoma.

[12]  M. Cazzola,et al.  Time-dependent changes in mortality and transformation risk in MDS. , 2016, Blood.

[13]  J. Chi,et al.  Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes , 2016, Hematology.

[14]  V. Milunović,et al.  The role of microRNA in myelodysplastic syndromes: beyond DNA methylation and histone modification , 2016, European journal of haematology.

[15]  Jiong Wu,et al.  Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer , 2015, Oncogene.

[16]  S. Barrans,et al.  Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. , 2015, Blood.

[17]  J. Bourhis,et al.  miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells , 2015, Oncoimmunology.

[18]  F. Lo‐Coco,et al.  A miRNA Signature in Human Cord Blood Stem and Progenitor Cells as Potential Biomarker of Specific Acute Myeloid Leukemia Subtypes , 2015, Journal of cellular physiology.

[19]  P. Huang,et al.  MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2 , 2015, Tumor Biology.

[20]  J. Chen,et al.  MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets , 2014, Oncogene.

[21]  C. Sarkar,et al.  Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing , 2014, BMC Genomics.

[22]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[23]  Rongxia Liao,et al.  Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia , 2013, Hematology.

[24]  Adam Williams,et al.  The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis. , 2013, Immunity.

[25]  R. Agami,et al.  Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer , 2013, Cell cycle.

[26]  S. Erkeland,et al.  MicroRNAs: key players of normal and malignant myelopoiesis , 2012, Current opinion in hematology.

[27]  A Kohlmann,et al.  Gene expression profiling in MDS and AML: potential and future avenues , 2011, Leukemia.

[28]  C. Croce,et al.  Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes , 2011, British journal of haematology.

[29]  W. Hofmann,et al.  Molecular mechanisms involved in the progression of myelodysplastic syndrome. , 2010, Future oncology.

[30]  X. Wang,et al.  Identification of microRNA‐181 by genome‐wide screening as a critical player in EpCAM–positive hepatic cancer stem cells , 2009, Hepatology.

[31]  J. Boultwood,et al.  Gene expression profiling in the myelodysplastic syndromes , 2005, Hematology.